Advocate Outlines Resources for Chronic Myeloid Leukemia Population
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Assessing the Future With “Promising” Antibody Drug Conjugates in Breast Cancer
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Mitigating ILD Following T-DXd in HR+, HER2-Low Metastatic Breast Cancer
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Applying Updated Breast Cancer Findings From ASCO to Clinical Practice
Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.
Ensuring Quality of Life in Chronic Myeloid Leukemia Populations
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Formulating Questions for Clinicians to Understand a CML Diagnosis
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Defining Goals of Therapy in Chronic Myeloid Leukemia
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Mitigating Toxicity and Monitoring QOL in Chronic Myeloid Leukemia
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Antitumor Activity Seen With Olverembatinib in GIST Subtype
Olverembatinib has shown promising clinical efficacy in SDH-deficient gastrointestinal stromal tumors, says Haibo Qiu, MD.
Determining Treatment Courses for a Chronic Myeloid Leukemia Diagnosis
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
TTFields Combo Prolongs Time to Progression in NSCLC Brain Metastasis Group
Phase 3 data also show an improvement in deterioration-free survival with TTFields and best supportive care in those with NSCLC and brain metastases.
Nivolumab Combo Yields Enduring Survival Vs Chemo in Metastatic NSCLC
Long-term data from the CheckMate 9LA trial support nivolumab/ipilimumab plus chemotherapy as frontline treatment for metastatic NSCLC.
Petosemtamab Combo Shows Responses, Tolerability in Head and Neck Cancer
Phase 2 data may support petosemtamab as a best-in-class treatment for frontline HNSCC, according to Jérôme Fayette, MD.
Novel Adenovirus Combo Elicits Immune Responses in Stage III/IV NSCLC
Most treatment-related adverse effects reported with CAN-2409 plus valacyclovir in a phase 2 trial were grade 1 or 2.
Clinical CRs Seen in Entire Dostarlimab dMMR Rectal Cancer Cohort
No patients with dMMR rectal cancer enrolled on a phase 2 study required subsequent chemotherapy or radiation following treatment with dostarlimab.
EFS Improvement Observed With Perioperative Nivolumab in Stage III N2/non-N2 NSCLC
CheckMate 77T trial saw an EFS improvement with neoadjuvant nivolumab in stage III N2 and stage III non-N2 non–small cell lung cancer.
Intracranial Control Seen With Dato-DXd in NSCLC Brain Metastasis Subgroups
Phase 2 data support further evaluation of datopotamab deruxtecan in patients with non–small cell lung cancer and brain metastases.
Durable EFS Noted in Nivolumab/Chemo in Resectable NSCLC
The CheckMate 816 trial reinforced the EFS data of nivolumab plus chemotherapy in resectable NSCLC.
Adjuvant Atezolizumab Sustains Survival Vs BSC in Stage IB to IIIA NSCLC
Final DFS results from IMpower010 show consistent survival when adjuvant atezolizumab was used in stage IB to IIIA NSCLC.
Multi-Peptide Vaccine Combo Shows Tolerability in Metastatic MSS CRC
Phase 2 data show that vaccination with PolyPEPI1018 may enhance the efficacy of atezolizumab in those with microsatellite stable metastatic CRC.
Camrelizumab Combo Improves PFS/OS Vs Sorafenib in Advanced HCC
The median progression-free survival and overall survival was extended with rivoceranib among those with unresectable HCC in the CARES-310 trial.
5-Year OS Rates Improve After Liver Transplant Plus Chemo CRC With Liver Metastasis
The addition of liver transplant to chemotherapy in those with colorectal cancer and liver metastases boosted overall survival.
Sustained Responses Achieved With Zanidatamab in HER2+ Biliary Tract Cancer
The safety profile of zanidatamab in the HERIZON-BTC-01 trial appears to remain consistent after longer follow-up.
T-DXd Boosts PFS Vs Chemo in HR+, HER2-Low Metastatic Breast Cancer
Secondary end points such as overall survival also appear to favor T-DXd among this breast cancer population in the phase 3 DESTINY-Breast06 trial.
Inavolisib Combo Reduces Time to Subsequent Treatment in Breast Cancer
Data also show a longer median time to deterioration for patients in the inavolisib arm in phase 3 INAVO120 trial.
Sustained Responses Achieved With Taletrectinib in ROS1-Positive NSCLC
Phase 2 data also show activity in diseases with resistance mutations such as G2032R with taletrectinib.
Pembrolizumab/Sacituzumab Govitecan Does Not Statistically Improve PFS in HR+ Breast Cancer
A trend towards improved progression-free survival was not noted when pembrolizumab plus sacituzumab govitecan was used to treat patients with HR+ breast cancer.
Method of Palliative Care Does Not Affect QOL in Advanced NSCLC
Either telehealth or in-person recipes of palliative care did not impact the quality of life outcomes for patients with advanced non–small cell lung cancer.
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
The combination of perioperative chemotherapy plus FLOT improved overall survival vs neoadjuvant chemoradiation in patients with resectable esophageal cancer.
Osimertinib Improves PFS in Advanced EGFR+ NSCLC
Osimertinib may become a new standard of care for those with EGFR-mutant NSCLC, according to Suresh S. Ramalingam, MD, FACP, FASCO.
